Bioventus Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
BVS$11.02+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Class A Common Stock · Class B Common Stock · Additional Paid-in Capital · Accumulated other comprehensive income (loss) · Accumulated Deficit · Non-controlling Interest · Total Stockholders’Equity | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||||||||||||
| December 31, 2021 | 59,548,504 | $59 | 15,786,737 | $16 | $473,318 | $179 | $(6,602) | $140,686 | $607,656 | ||||||||
| Issuance of Class A common stock for equity plans | 2,514,510 | 3 | — | — | 5,819 | — | — | — | 5,822 | ||||||||
| Deferred taxes on equity rebalancing | — | — | — | — | (1,977) | — | — | — | (1,977) | ||||||||
| Net loss | — | — | — | — | — | — | (158,704) | (54,687) | (213,391) | ||||||||
| Tax withholdings on equity-based compensation awards | — | — | — | — | (3,352) | — | — | — | (3,352) | ||||||||
| Deconsolidation of noncontrolling interest | — | — | — | — | — | — | — | 247 | 247 | ||||||||
| Equity-based compensation | — | — | — | — | 14,180 | — | — | 3,405 | 17,585 | ||||||||
| Change in noncontrolling interest allocation | — | — | — | — | 2,588 | — | — | (2,588) | — | ||||||||
| Other comprehensive loss | — | — | — | — | — | (289) | — | (79) | (368) | ||||||||
| December 31, 2022 | 62,063,014 | $62 | 15,786,737 | $16 | $490,576 | $(110) | $(165,306) | $86,984 | $412,222 | ||||||||
| Issuance of Class A common stock for equity plans | 1,204,422 | 1 | — | — | 777 | — | — | — | 778 | ||||||||
| Net loss | — | — | — | — | — | — | (156,230) | (39,395) | (195,625) | ||||||||
| Equity-based compensation | — | — | — | — | 2,388 | — | — | 334 | 2,722 | ||||||||
| Change in noncontrolling interest allocation | — | — | — | — | 513 | — | — | (513) | — | ||||||||
| Distributions to members | — | — | — | — | — | — | — | (111) | (111) | ||||||||
| Other comprehensive income | — | — | — | — | — | 904 | — | 228 | 1,132 | ||||||||
| December 31, 2023 | 63,267,436 | $63 | 15,786,737 | $16 | $494,254 | $794 | $(321,536) | $47,527 | $221,118 | ||||||||
| Issuance of Class A common stock for equity plans | 2,490,905 | 3 | — | — | 2,439 | — | — | — | 2,442 | ||||||||
| Net loss | — | — | — | — | — | — | (33,542) | (10,291) | (43,833) | ||||||||
| Equity-based compensation | — | — | — | — | 8,321 | — | — | 1,737 | 10,058 | ||||||||
| Change in noncontrolling interest allocations | — | — | — | — | 495 | — | — | (495) | — | ||||||||
| Other comprehensive loss | — | — | — | — | — | (3,367) | — | (814) | (4,181) | ||||||||
| December 31, 2024 | 65,758,341 | $66 | 15,786,737 | $16 | $505,509 | $(2,573) | $(355,078) | $37,664 | $185,604 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.